Chase AIPricingFAQs
Display currency
Loading news…

OriCiro Genomics

ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring).
Tokyo, Japan Founded 2018 1-10 employees For Profit

OriCiro Genomics develops and commercializes cell-free synthesis and amplification technologies of large DNA molecules.

OriCiro Genomics was acquired by Moderna in 2023 for $85M.
Total Funding
Available in Pro
Last Funding
Available in Pro
Acquisitions
0
Monthly Visits
Available in Pro
Contacts
0
Patents
2

Company Details

Funding & Financials

Pro
Total funding
Funding rounds
Last funding
Last funding type
Last funding date
Funding status
Total equity funding
Revenue range

IPO & Stock

IPO status
Private

Web Traffic

Pro
Monthly visits
Global traffic rank
6-mo avg visits
Visit duration (s)
Pages / visit
Bounce rate
Rank change (mo)

Technology & IP

Active technologies
18
Patents granted
2
Trademarks
0
Top patent class
Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering
IT spend
$9M

Company Info

Founded
2018
Employees
1-10
Operating status
Closed
Company type
For Profit
Org types
company
Founders
1
News articles
8
HQ
Tokyo, Japan
Region
Asia-Pacific (APAC)
Exit date
Jan 4, 2023

Signals & Scores

Heat score
Low
Trend (7d)
0
Trend (30d)
0
Trend (90d)
-0.3
Last leadership hire
Jul 20, 2021

Key People at OriCiro Genomics

President and CEO
CTO
Co-Founder

Explore 200,000+ acquisitions — free

Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.

Explore all acquisitions

Recent News related to OriCiro Genomics

Loading news…

FAQs about OriCiro Genomics

People who checked this page also checked these

Browse the full Acquirezy directory.
OriCiro Genomics - Company Profile, Full Acquisitions List, Funding and Investments